MetaCap

Enanta Pharmaceuticals (ENTA) vs Rocket Pharmaceuticals (RCKT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rocket Pharmaceuticals (RCKT) has outperformed Enanta Pharmaceuticals (ENTA) over the past year, losing 33.4% versus a loss of 40.1%. Over five years, ENTA leads with a -91.7% price change compared with -91.8% for RCKT. Enanta Pharmaceuticals is the larger company by market cap ($222.2 million vs $217.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENTA-40.14%RCKT-33.45%
+87%+20%-46%
Nov 21, 20251 yearNov 20, 2026
ENTA-89.88%RCKT-93.00%
+28%-36%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENTA versus RCKT key metrics
MetricENTARCKT
Share price$7.62$1.95
Market cap$222.19M$217.74M
1-day change-4.51%-7.58%
YTD return-51.68%-44.44%
1-year return-40.14%-33.45%
5-year return-91.71%-91.76%
EPS (TTM)$-2.35$-0.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$63.00M$0
Revenue growth (YoY)-3.56%—
Net income (latest FY)$-68.25M$-223.12M
Operating margin-99.01%—
Net margin-108.33%—
52-week high$17.15$5.45
52-week low$7.56$1.94
Distance from 52-week high-55.57%-64.22%
Analyst consensusstrong_buybuy
Avg. price target upside+186.48%+326.15%
Average volume287.81K1.90M
Shares outstanding29.16M111.66M
Employees120202
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Enanta Pharmaceuticals

ENTA stock →

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees

About Rocket Pharmaceuticals

RCKT stock →

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.

Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees

ENTA vs RCKT FAQ

Which is bigger, Enanta Pharmaceuticals or Rocket Pharmaceuticals?

Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $222.19M compared with $217.74M for Rocket Pharmaceuticals (RCKT).

Which stock has performed better over the past year, ENTA or RCKT?

RCKT returned -33.45% over the past 12 months, compared with -40.14% for ENTA (price return, excluding dividends). Past performance does not predict future results.

Are Enanta Pharmaceuticals and Rocket Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons